Comparative characterization of experimental and calculated lipophilicity and anti-tumour activity of isochromanone derivatives

Current Medicinal Chemistry

Volumn 17, Issue 4, 2010, Pages 321-333

  Huszar M ^a   Varga, A ^a   Horvath A ^a   Lorand T ^b   Agocs A ^b   Idei, M ^a   Mandl, J ^a   Vantus T ^a   Keri G ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Antiproliferative effect; Apoptosis; Isochromanone derivative; Lipophilicity

Indexed keywords

4 CHROMANONE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG SOLUBILITY; DRUG SYNTHESIS; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIPOPHILICITY; MOLECULAR LIBRARY;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; CHROMONES; DRUG DISCOVERY; FLOW CYTOMETRY; HUMANS; HYDROPHOBICITY; IMMUNOBLOTTING; INHIBITORY CONCENTRATION 50; MICROSCOPY;

EID: 77950652336     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790192703     Document Type: Article

References (84)

1. Hansch, C.; Leo, A. Exploring QSAR Fundamentals and Applications in Chemistry and Biology, American Chemical Society: Washington, 1995.
2. Terrett, N. K.; Gardner, M.; Gordon, D. W.; Kobylecki, R. J.; Steele, J. Combinatorial synthesis - the design of compound libraries and their application to drug discovery. Tetrahedron, 1995, 51, 8135-8173.
3. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23, 3-25.
4. Rishton, G. M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov. Today, 2003, 8, 86-96.
5. Van de Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker D. K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem., 2001, 44, 1313-1333. (Pubitemid 32852106)
6. Valkó, K. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. J. Chromatogr. A, 2004, 1037, 299-310. (Pubitemid 38591346)
7. Alonso, M. M.; Asumendi, A.; Villar, J.; Gil, M. J.; Martínez- Merino, V.; Encío, I.; Migliaccio, M. New benzo(b)thiophenesulphonamide 1,1-dioxide derivatives induce a reactive oxygen species-mediated process of apoptosis in tumour cells. Oncogene, 2003, 22, 3759-3769. (Pubitemid 36760738)
8. Villar, R.; Encio, I.; Migliaccio, M.; Gila, M. J.; Martinez-Merino, V. Synthesis and cytotoxic activity of lipophilic sulphonamide derivatives of the benzo[b]thiophene 1,1-dioxide. Bioorgan. Med. Chem., 2004, 12, 963-968.
9. Encío, I.; Morré, D.J.; Villar, R.; Gil, M. J.; Martínez-Merino, V. Benzo[b]thiophenesulphonamide 1,1-dioxide derivatives inhibit tNOX activity in a redox state-dependent manner. Br. J. Cancer, 2005, 92, 690-695.
10. Yu, Y.; Lou, L; Liu, W.; Zhu, H.; Ye, Q.; Chen, X.; Gao W.; Hou S. Synthesis and anticancer activity of lipophilic platinum(II) complexes of 3,5-diisopropylsalicylate. Eur. J. Med. Chem., 2008, 43, 1438-1443. (Pubitemid 351885211)
11. Woerdenbag, H.; Moskal, T.; Pras, N.; Malingré, T. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J. Nat. Prod., 1993, 56, 849-856. (Pubitemid 23195612)
12. John, G.; Shrivastava, R.; Chevalier, A.; Pognat J.; Massingham R. An in vitro investigation of the relationships between potency, lipophilicity, cytotoxicity and chemical class of representative calcium antagonist drugs. Pharmacol. Res., 1993, 27, 253-262. (Pubitemid 23191719)
13. Xue, L.; Bajorath, J. Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening. Comb. Chem. High T. Scr., 2000, 3, 363.
14. Braumann, Th.; Weber, G.; Grimme, L. H. Quantitative structure-activity relationships for herbicides: Reversed-phase liquid chromatographic retention parameter, log kw, versus liquid-liquid partition coefficient as a model of the hydrophobicity of phenylureas, s-triazines and phenoxycarbonic acid derivatives. J. Chromatogr., 1983, 261, 329-343.
15. Lambert, W. J. Modeling oil - water partitioning and membrane permeation using reversed-phase chromatography. J. Chromatogr., 1993, 656, 469-484.
16. Valkó, K.; My Du, Ch.; Bevan, C.; Reynolds D. P; Abraham, M. H. Rapid Method for the Estimation of Octanol/Water Partition Coefficient (Log Poct) from Gradient RP-HPLC Retention and a Hydrogen Bond Acidity Term (Σα2H). Curr. Med. Chem., 2001, 8, 1137-1146. (Pubitemid 32633663)
17. Escuder-Gilabert, L.; Martinez-Pla, J. J.; Sagrado, S.; Villanueva-Camanas, R. M.; Medina-Hernández, M. J. Biopartitioning micellar separation methods: modelling drug absorption. J. Chromatogr. B, 2003, 797, 21-35.
18. Vallat, P.; Fan, W.; Tayar, N. El.; Carrupt, P. A.; Testa, B. Solvatochromic analysis of the retention mechanism of two novel stationary phases used for measuring lipophilicity by RP-HPLC. J. Liquid Chromatogr., 1992, 15, 2133.
19. Hansch, C.; Leo, A. Substituent Constants for Correlation Analysis in Chemistry and Biology. Wiley: New York, 1979.
20. Takács-Novák, K. Computerized logP prediction using fragment methods. Acta Pharm. Hung., 1998, 68, 39-48. (in Hungarian) (Pubitemid 28141166)
21. Djakovic-Sekulic, T.; Acanski, M.; Perisic-Janjic, N. Evaluation of the predictive power of calculation procedure for molecular hydrophobicity of some estradiol derivates. J. Chromatogr. B, 2002, 766, 67-75. (Pubitemid 34142377)
22. Carrupt, P. A.; Testa, B.; Gaillard, P. In Computational Approaches to Lipophilicity: Methods and Applications; K. B. Lipkowitz, B. D. Boyd, Eds.; Rev. Computat. Chem. New York, 1997; Vol. 11, pp. 241-315.
23. Albert, A. Relations between molecular structure and biological activity: stages in the evolution of current concepts. Annu. Rev. Pharmacol., 1971, 11, 13-36.
24. Burgen, A. S. Conformational changes and drug action. Fed. Proc., 1981, 40, 2723-2728.
25. Chohan, K. K.; Paine, S. W.; Waters, N. J. Quantitative structure activity relationships in drug metabolism. Curr. Top. Med. Chem., 2006, 6, 1569-1578. (Pubitemid 44304615)
26. Barrett, I.; Meegan, M. J.; Hughes, R. B.; Carr, M.; Knox, A. J. S.; Artemenko, N.; Golfis, G.; Zisterer, D. M.; Lloyd, D. G. Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators. Bioorg. Med. Chem., 2008, 16, 9554-9573.
27. Verma, R. P.; Hansch, C. Elucidation of structure-activity relationships for 2- or 6-substituted-5,8-dimethoxy-1,4-naphthoquinones. Bioorg. Med. Chem., 2004, 12, 5997-6009.
28. Matysiak, J. Evaluation of electronic, lipophilic and membrane affinity effects on antiproliferative activity of 5-substituted-2-(2,4-dihydroxyphenyl)- 1,3,4-thiadiazoles against various human cancer cells. Eur. J. Med. Chem., 2007, 42, 940-947. (Pubitemid 46907333)
29. Campos, J.; Nunez, M.C.; Conejo-Garcia, A.; Sanchez-Martin, R.M.; Hernandez-Alcoceba, R.; Rodriguez-Gonzalez, A.; Lacal, J.C.; Gallo, M.A.; Espinosa, A. QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be? Curr. Med. Chem., 2003, 10, 1095-1112. (Pubitemid 36758224)
30. Toth, I.; Christodoulou, M.;Bankowsky, K.; Flinn, N.; Gibbons, W. A.; Godeau, G.; Moczar, E.; Hornebeck, W. Design of potent lipophilic-peptide inhibitors of human neutrophil elastase: In vitro and in vivo studies. Int. J. Pharm., 1995, 125, 117-122.
31. Hornebeck, W.; Moczar, E.; Szecsi, J.; Robert, L. Fatty acid peptide derivatives as model compounds to protect elastin against degradation by elastases. Biochem. Pharmacol., 1985, 34, 3315-3321. (Pubitemid 16215696)
32. Lafuma, C.; Frisdal, E.; Robert, L.; Moczar, E.; Lefrancier, P.; Hornebeck, W. Lipopeptides as biofunctional inhibitors of elastase-induced emphysema in mice by intratracheal pretreatment with oleoyl-alanyl-alanyl- prolylvaline. In Aubry, A.; Marraud, M.; Vitoux, B., Eds; Second Forum on Peptides, Colloque INSERM / John Libbey Eurotext., 1989; Vol. 184, pp. 321-324.
33. Boduier, C.; Godeau, G.; Hornebeck, W.; Robert, L.; Bieth, J. G. the elastolytic activity of cathepsin G: An ex vivo study with dermal elastin. Am. J. Respir. Cell Mol. Biol., 1991, 4, 497-503.
34. Quartara, L.; Fabbri, G.; Ricci, R.; Patacchini, R.; Pestellini, V.; Maggi,C. A.; Pavone, V.; Giachetti, A.; Arcamone, F. Influence of lipophilicity on the biological activity of cyclic pseudopeptide NK-2 receptor antagonists. J. Med. Chem., 1994, 37, 3630-3638. (Pubitemid 24334618)
35. Regan, J.; Capolino, A.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Hickey, E.; Kroe, R. K.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C. A.; Swinamer, A.; Torcellini, C.; Tsang, M.; Moss, N. Structure-activity relationships of the p38r MAP kinase inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H- pyrazol-3-yl)-3-[4-(2-morpholin-4-ylethoxy) naphthalen-1-yl]urea (BIRB 796). J. Med. Chem., 2003, 46, 4676-4686.
36. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, G. A.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem., 2002, 45, 2994-3008. (Pubitemid 34721521)
37. Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M. S.; Mendel, D. B.; Tai, C. Y.; Laver, W. G.; Stevens, R. C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc., 1997, 119(4), 681-690. (Pubitemid 27101232)
38. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem., 2003, 46, 1250-1256.
39. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Disov., 2007, 6, 881-890. (Pubitemid 350042396)
40. Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; DeCrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett., 2008, 18, 4872-4875.
41. Waring, M. J.; Johnstone, C. A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett., 2007, 17, 1759-1764. (Pubitemid 46316777)
42. Gleeson, M. P. J. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem., 2008, 51, 817-834.
43. Waterhouse, R. N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol. Imaging Biol., 2003, 5(6), 376-389.
44. Coats, E. A.; Milstein, S. R.; Pleiss, M. A.; Roesener J. A. Comparative analysis of the cytotoxicity of substituted [phenylglyoxal bis(4-methyl-3- thiosemicarbazone)]copper(II) chelates. 2. Parabolic correlations and their implications for selective toxicity. J. Med. Chem., 1978, 21, 804-809. (Pubitemid 8391124)
45. Waring, M. J. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. Bioorg. Med. Chem. Lett., 2009, 19, 2844-2851.
46. Takahashi, K.; Kunishiro, K.; Kasai, M.; Miike, T.; Kurahashi, K.; Shirahase, H. Relationships between lipophilicity and biological activities in a series of indoline-based anti-oxidative acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors. Arzneimittelforschung, 2008, 58(12), 666-672
47. Pop, E.; Oniciu, D. C.; Pape, M. E.; Cramer, C. T.; Dasseux H. J.-L. Lipophilicity parameters and biological activity in a series of compounds with potential cardiovascular applications. Croat. Chem. Acta, 2004, 77, 301-306.
48. Fahr, A.; van Hoogevest|, P.; Kuntsche, J.; Leigh L. S. M.|: Lipophilic drug transfer between liposomal and biological membranes: what does it mean for parenteral and oral drug delivery? J. Liposome Res., 2006, 16, 281-301.
49. Veldman, R. J.; Zerp, S.; Van Blitterswijk, W. J.; Verheij, M. Nhexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. Br. J. Cancer, 2004, 90, 917-925. (Pubitemid 38406607)
50. Levin, VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem., 1980, 23, 682-684.
51. Atkinson, F.; Cole, S.; Green, C.; van de Waterbeemd, H. Lipophilicity and other parameters affecting brain penetration. Curr. Med. Chem.-Central Nervous System Agents, 2002, 2, 229-240.
52. Ballet, S.; Misicka, A.; Kosson, P.; Lemieux, C.; Chung, N; Schiller, P.W.; Lipkowski, A. W.; Tourwé, D. Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J. Med. Chem., 2008, 51, 2571-2574. (Pubitemid 351628519)
53. De Lange, E. C.- M.; de Boer, B. A. G.; Breimer, D. D. Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv. Drug Deliv. Rev., 1999, 36, 211-227.
54. Gimenez, F.; Fernandez, C.; Mabondzo, A. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, p-glycoprotein and multidrug resistance proteins. J. Acq. Immun. Def. Synd., 2004, 36, 649-658. (Pubitemid 38685958)
55. Timmermans, P. B. M. W. M.; Brands, A.; van Zwieten, P.A. Lipophilicity and brain disposition of clonidine and structurally related imidazolidines. N-S. Arch. Pharmacol., 1977, 300, 217-226.
56. Dimmock, J. R.; Wong, M. L. C. Bioactivities and potential uses in drug design of acyclic α ,β -unsaturated ketones. Can. J. Pharm. Sci., 1976, 11, 35-53.
57. Geiger, H. In The Flavanoids; Harborne J. B, Ed.; Chapman & Hill Ltd: London, 1988; pp. 389-397.
58. Ammar, M. S.; Gerber, N. N.; Mc Daniel, L. E. New antibiotic pigments related to fusarubin from fusarium solani (MART.) sacc. J. Antibiot., 1979, 32, 679-684.
59. Ravisé; Kirkiacharian, B. S. Effect of the structure of phenolic compounds on the growth inhibition of Phytophthora parasitica and the activity of parasitogenic enzymes. III. Homo-isoflavanones. Phytopath. Zeitschrift, 1978, 92(1), 36-50.
60. Kern, H. The naphthazarins of fusarium. Ann. Phytopathol., 1978, 10, 327-345.
61. Casellas, M.; Grifoll, M.; Bayona, J. M.; Solanas, A. M. New metabolites in the degradation of fluorene by Arthrobacter sp. strain F101. Appl. Environ. Microbiol., 1997, 63(3), 819-826.
62. Al-Nakib, T. M.; Bezjak, V.; Meegan, M. J.; Chandy, R. Synthesis and antifungal activity of some 3-benzylidenechroman-4-ones, 3- benzylidenethiochroman-4-ones and 2-benzylidene-1-tetralones. Eur. J. Med. Chem., 1990, 25, 455-462.
63. Lóránd, T.; Al-Nakib, T. M.; Prókai, L. Synthesis, Antimycotic Activity and QSAR Studies of Homoisoflavanone Analogues, 212th National Meeting of the American Chemical Society: Orlando, FL, USA, 1996.
64. AL-Nakib, T. M.; Lóránd, T.; Földesi, A.; Varghese, R. The in vitro antimycotic activity and acute toxicity of third-generation benzylidenetetralones and heteroarylidenetetralones. Med. Prin. Pract., 2001, 10, 191-196. (Pubitemid 34062909)
65. Lampronti, I.; Martello, D.; Bianchi, N.; Borgatti, M.; Lambertini, E.; Piva, R.; Jabbar, S.; Shahabuddin Kabir Choudhuri, M.; Tareq Hassan Khan, M.; Gambari, R. In vitro antiproliferative effects on human tumor cell lines of extracts from the Bangladeshi medicinalplant Aeglemarmelos Correa. Phytomedicine, 2003, 10(4), 300-308 (Pubitemid 36597166)
66. Serenex, Inc., Kenneth, H.; Philip, H.; Thomas, B.; James, V. Dihidropyridazine, Tetrahydropyridine, Chromanone and Dihydronaphthalenone Derivatives as Heat-Shock Protein 90 Inhibitors. 2008
67. Hallgas, B.; Dobos, Zs.; Ocombining double acute accentsz, E.; Hollósy, F.; Schwab, R. E.; Szabó, E. Z.; Erocombining double acute accents, D.; Idei, M.; Kéri G.; Lóránd, T. Characterization of lipophilicity and antiproliferative activity of E-2-arylmethylene-1-tetralones and their heteroanalogues. J. Chromatogr. B, 2005, 819(2), 283-291
68. Hallgas, B.; Dobos, Zs.; Agócs, A.; Idei, M.; Kéri, G.; Loránd, T.; Mészáros, G. Lipophilicity and antiproliferative activity profiling of 2-benzylidencycloalkanones. J. Chromatogr. B, 2007, 856, 148-155.
69. Keresztury, G.; Holly, S.; Sundius, T.; Loránd, T. Analysis of vibrational spectra of some new E- and Z-4-arylidene-3-isochromanones. Vib. Spectrosc., 2002, 29, 53-59. (Pubitemid 34660606)
70. Lóránd, T.; Forgó, P.; Földesi, A.; Ocombining double acute accentsz, E.; Prókai, L. Improved solvent-free synthesis and structure elucidation of (E)- and (Z)-4-(arylmethylene)-3-isochromanones. Eur. J. Org. Chem., 2002, 17, 2996-3003.
71. Huszár, M.; Hallgas, B.; Idei, M.; Kiss-Szikszai, A.; Horváth, A.; Patonay, T. Lipophilicity of substituted aurones and related compounds measured on immobilized artificial membrane (IAM) and conventional C8 (MOS) columns. J. Liq. Chromatogr., 2008, 31, 3143-4158.
72. Verzola, B.; Gelpi, C.; Righetti, P. G. Quantitative studies on the adsorption of proteins to the bare silica wall in capillary electrophoresis: II. effects of adsorbed, neutral polymers on quenching the interaction. J. Chromatogr. A, 2000, 874, 293-303.
73. Corradini, D.; Kalghatgi, K.; Horváth, C.S. Effect of mobile phase additives on peptide retention in reversed-phase chromatography with pellicular and totally porous sorbents. J. Chromatogr. A, 1996, 728/1-2, 225-233.
74. Opperhuizer, A.; Sinnige, T. L.; van der Steen, J. M. D.; Hutzinger, O. Differences between retentions of various classes of aromatic hydrocarbons in reversed-phase high-performance liquid chromatography: Implications of using retention data for characterizing hydrophobicity. J. Chromatogr. B, 1987, 388, 51-64.
75. Melander, W. R.; Chen, B.-K.; Horváth, Cs. mobile phase effects in reversed-phase chromatography: VII. Dependence of retention on mobile phase composition and column temperature. J. Chromatogr. A, 1985, 318, 1-10.
76. Snyder, L. R.; Kirkland, J. J. Introduction to Modern Liquid Chromatography, John Wiley and Sons: New York, 1974.
77. Poole, C. F. The essence of chromatograph79. Elsevier: Amsterdam, 2003.
78. Oliver, M. H.; Harrison, N. K.; Bishop, J. E.; Cole, P. J.; Laurent, G. J. A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J. Cell. Sci., 1989, 92(3), 513-518.
79. Herrmann, M.; Lorenz, H. M.; Vollm, R.; Grucombining double acute accentnkem, M.; Woithm, W.; Kaldenm, J. R. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res., 1994, 22, 5506-5507.
80. Hallgas, B.; Patonay, T.; Kiss-Szikszai, A.; Dobos, Zs.; Hollósy, F.; Kéri, G.; Erocombining double acute accents, D.; Ocombining double acute accentrfi, L.; Idei, M. Comparison of measured and calculated lipophilicity of substituted aurones and related compounds. J. Chromatogr. B, 2004, 801, 229-235.
81. Hollósy, F.; Seprocombining double acute accentdi, J.; Ocombining double acute accentrfi, L.; Erocombining double acute accents, D.; Kéri G.; Idei. M. Evaluation of lipophilicity and antitumour activity of parallel carboxamide libraries. J. Chromatogr. B, 2002, 780, 355-363.
82. Fish, P. V.; Ryckmans, T.; Stobie, A.; Wakenhut, F. [4-(Phenoxy)pyridin- 3-yl]methylamines: A new class of selective noradrenaline reuptake inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 1795-1798.
83. Allen, D. M. The relationship between variable selection and data augmentation and a method for prediction. Technometrics, 1974, 16, 125-127.
84. Seamus, J.; Martin and Green, D. R. Protease activation during apoptosis: death by a thousand cuts? Cell, 1995, 82, 349-352.